Edinburgh Worldwide: stock spotlight on Alnylam

Discover how US drugmaker Alnylam is transforming from a rare disease specialist into a major therapeutic platform company and why the Edinburgh Worldwide team remain confident in the significant long-term potential. Capital at risk.

Read more >

Editor's Picks

Loading...